543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies
Jay A. Grobler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Julie Strizki(Merck & Co., Inc., Rahway, NJ, USA (United States)), Nicholas Murgolo(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yang Luo(Aaron Diamond AIDS Research Center), Jiejun Du(Merck & Co., Inc., Rahway, NJ, USA (United States)), David D. Ho(Columbia University), Wei Gao(Fujian Medical University), Manoj S. Nair(Aaron Diamond AIDS Research Center), Youfang Cao(United States Military Academy), Daria J. Hazuda(Quantitative BioSciences), Ying Zhang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Yaoxing Huang(Aaron Diamond AIDS Research Center)
Cited by 10
Related Papers
Identification of a Reservoir for HIV-1 in Patients on Highly Active Antiretroviral Therapy
|Science|1997|3.1k
Dramatic Rise in Plasma Viremia after CD8+ T Cell Depletion in Simian Immunodeficiency Virus–infected Macaques
|The Journal of Experimental Medicine|1999|1.4k